Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Recs

2
Player Avatar Ewok82 (29.15) Submitted: 8/28/2009 3:05:04 AM : Underperform Start Price: $6.50 IMMU Score: +5.78

A big winner or hype?
The idea of creating antibodies to difficult to treat tumor cells and then attaching the antibody to a toxic agent to selectively kill tumor cells has been around for a while. Did this company find a way to do this cost effectively and with adequate safety?
If is works, will there be funding for it?
With this price spike, some people must believe in it, but even good idea can die in this market.

Featured Broker Partners


Advertisement